ERBB2 and neoplasm: When comparing the uPA/PAI-1-cohort with the entire study cohort, the uPA/PAI-1-cohort had 3.8% more sHR positive tumours (85.5% vs. 81.7%) and 2.6% fewer HER2-positive tumours (14,0% vs. 16.5%) (χ2 test; p < 0.05), reflecting the use of neoadjuvant therapy with less available tumour tissue in sHR-negative tumours (Supplementary Table S1).